Replies to post #140507 on Biotech Values

[mcbio]

Perhaps, but it depends on the constituent drugs in the cocktail. For some combinations, ribavirin may prove to be superfluous.

That's probably right, but the key I think will be the number of HCV DAAs needed. Will just two suffice in the absence of ribavirin or will it be more likely that a three-drug regimen will be needed? Will be interesting to see how it plays out.